David Geldmacher

Summary

Affiliation: University of Virginia
Country: USA

Publications

  1. ncbi Differential diagnosis of dementia syndromes
    David S Geldmacher
    Department of Neurology, University of Virginia Health System, P O Box 800394, Charlottesville, VA 22908, USA
    Clin Geriatr Med 20:27-43. 2004
  2. pmc Cost-effectiveness of drug therapies for Alzheimer's disease: A brief review
    David S Geldmacher
    Department of Neurology, University of Virginia Health System Charlottesville, VA, USA
    Neuropsychiatr Dis Treat 4:549-55. 2008
  3. doi Alzheimer disease prevention: focus on cardiovascular risk, not amyloid?
    David S Geldmacher
    Department of Neurology, University of Virginia Health System, Charlottesville, VA, USA
    Cleve Clin J Med 77:689-704. 2010
  4. ncbi Donepezil (Aricept) for treatment of Alzheimer's disease and other dementing conditions
    David S Geldmacher
    Department of Neurology, University of Virginia Health System, PO Box 800394, Charlottesville, VA 22908, USA
    Expert Rev Neurother 4:5-16. 2004
  5. ncbi The cost benefit to health plans of pharmacotherapy for Alzheimer's disease
    David S Geldmacher
    Department of Neurology, University of Virginia Health System, Charlottesville, VA, USA
    Manag Care 14:44-6, 49-52, 54-5. 2005
  6. ncbi Dementia with Lewy bodies: diagnosis and clinical approach
    David S Geldmacher
    Department of Neurology, University of Virginia Health System, Charlottesville 22908, USA
    Cleve Clin J Med 71:789-90, 792-4, 797-8 passim. 2004
  7. ncbi Visuospatial dysfunction in the neurodegenerative diseases
    David S Geldmacher
    Department of Neurology, University of Virginia, PO Box 800394, Charlottesville, VA 22908, USA
    Front Biosci 8:e428-36. 2003
  8. ncbi Alzheimer's disease: current pharmacotherapy in the context of patient and family needs
    David S Geldmacher
    Memory Disorders Program, Department of Neurology, University of Virginia, Charlottesville, USA
    J Am Geriatr Soc 51:S289-95. 2003
  9. doi A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease
    David S Geldmacher
    Department of Neurology, University of Virginia Health System, Charlottesville, USA
    Arch Neurol 68:45-50. 2011
  10. ncbi Conduction aphasia as a function of the dominant posterior perisylvian cortex. Report of two cases
    Mark Quigg
    Department of Neurology and Neurological Surgery, University of Virginia Health System, Charlottesville, Virginia 22908, USA
    J Neurosurg 104:845-8. 2006

Research Grants

  1. Pioglitazone in Alzheimer's Disease Progression
    David Geldmacher; Fiscal Year: 2001
  2. Pioglitazone in Alzheimer's Disease Progression
    David Geldmacher; Fiscal Year: 2002
  3. Pioglitazone in Alzheimer's Disease Progression
    David Geldmacher; Fiscal Year: 2003

Detail Information

Publications20

  1. ncbi Differential diagnosis of dementia syndromes
    David S Geldmacher
    Department of Neurology, University of Virginia Health System, P O Box 800394, Charlottesville, VA 22908, USA
    Clin Geriatr Med 20:27-43. 2004
  2. pmc Cost-effectiveness of drug therapies for Alzheimer's disease: A brief review
    David S Geldmacher
    Department of Neurology, University of Virginia Health System Charlottesville, VA, USA
    Neuropsychiatr Dis Treat 4:549-55. 2008
    ..The current state of evidence suggests that treatment decisions in AD should be based on assessment of benefit in individual patients rather than broader societal economic factors...
  3. doi Alzheimer disease prevention: focus on cardiovascular risk, not amyloid?
    David S Geldmacher
    Department of Neurology, University of Virginia Health System, Charlottesville, VA, USA
    Cleve Clin J Med 77:689-704. 2010
    ..Class I evidence for prevention is extremely limited. The overall body of evidence suggests the best time to intervene is in midlife, not in old age...
  4. ncbi Donepezil (Aricept) for treatment of Alzheimer's disease and other dementing conditions
    David S Geldmacher
    Department of Neurology, University of Virginia Health System, PO Box 800394, Charlottesville, VA 22908, USA
    Expert Rev Neurother 4:5-16. 2004
    ..Despite a sense of limited efficacy of this drug class among prescribers, number needed-to-treat analyses suggest donepezil is highly effective at reducing the long-term adverse outcomes associated with Alzheimer's disease...
  5. ncbi The cost benefit to health plans of pharmacotherapy for Alzheimer's disease
    David S Geldmacher
    Department of Neurology, University of Virginia Health System, Charlottesville, VA, USA
    Manag Care 14:44-6, 49-52, 54-5. 2005
    ..Pharmacoeconomic studies indicate that donepezil and memantine treatment may reduce total costs of care for AD patients and their caregivers, with potential economic benefits to MCOs...
  6. ncbi Dementia with Lewy bodies: diagnosis and clinical approach
    David S Geldmacher
    Department of Neurology, University of Virginia Health System, Charlottesville 22908, USA
    Cleve Clin J Med 71:789-90, 792-4, 797-8 passim. 2004
    ..Dementia with Lewy bodies (DLB) is a common form of dementia that is being increasingly recognized. This paper reviews this disorder, emphasizing how it is different from other causes of dementia...
  7. ncbi Visuospatial dysfunction in the neurodegenerative diseases
    David S Geldmacher
    Department of Neurology, University of Virginia, PO Box 800394, Charlottesville, VA 22908, USA
    Front Biosci 8:e428-36. 2003
    ..In addition, the functional impact of the deficits is addressed...
  8. ncbi Alzheimer's disease: current pharmacotherapy in the context of patient and family needs
    David S Geldmacher
    Memory Disorders Program, Department of Neurology, University of Virginia, Charlottesville, USA
    J Am Geriatr Soc 51:S289-95. 2003
    ..Numerous additional choices are available to the clinician for pharmacotherapy of adverse behaviors. Community-based psychoeducational support is also of value to caregivers...
  9. doi A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease
    David S Geldmacher
    Department of Neurology, University of Virginia Health System, Charlottesville, USA
    Arch Neurol 68:45-50. 2011
    ..To evaluate the safety of the peroxisome proliferator-activated receptor gamma agonist pioglitazone in nondiabetic patients with Alzheimer disease (AD) and to explore treatment effect sizes on clinical outcomes...
  10. ncbi Conduction aphasia as a function of the dominant posterior perisylvian cortex. Report of two cases
    Mark Quigg
    Department of Neurology and Neurological Surgery, University of Virginia Health System, Charlottesville, Virginia 22908, USA
    J Neurosurg 104:845-8. 2006
    ..These cases demonstrate a localization of language repetition to the posterior perisylvian cortex. Brain mapping of this region should include assessment of verbal repetition to avoid potential deficits resembling conduction aphasia...
  11. ncbi Donepezil in vascular dementia: a viewpoint by David S. Geldmacher
    David S Geldmacher
    Department of Neurology, University of Virginia Health System, Charlottesville, Virginia, USA
    Drugs Aging 20:1137. 2003
  12. pmc Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial
    Robert C Green
    Department of Neurology, Boston University School of Medicine, 72 E Concord St, L 320, Boston, MA 02118, USA
    JAMA 302:2557-64. 2009
    ..Tarenflurbil, a selective Abeta(42)-lowering agent, demonstrated encouraging results on cognitive and functional outcomes among mildly affected patients in an earlier phase 2 trial...
  13. ncbi Alzheimer's disease and dementia
    David S Geldmacher
    Department of Neurology, University of Virginia Health System, P O Box 800394, Charlottesville, VA 22908, USA
    Clin Geriatr Med 20:XI-XII. 2004
  14. ncbi Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial
    Sandra Black
    University of Toronto, Department of Medicine Division of Neurology, Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario, Canada
    Stroke 34:2323-30. 2003
    ..Clinical observations suggest that patients with vascular dementia (VaD) may benefit from treatment with cholinesterase inhibitors. This study evaluated the efficacy and safety of donepezil for relieving symptoms of dementia in VaD...
  15. ncbi Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease
    David S Geldmacher
    University Memory and Aging Center, University Hospitals Research Institute, Cleveland, Ohio, USA
    J Am Geriatr Soc 51:937-44. 2003
    ..To assess the relationship between donepezil treatment and time to nursing home placement (NHP) for patients with Alzheimer's disease (AD)...
  16. ncbi Cost-effective recognition and diagnosis of dementia
    David S Geldmacher
    Case Western Reserve University, Cleveland, Ohio, USA
    Semin Neurol 22:63-70. 2002
    ..As their patient population ages, physicians need to learn to recognize the early symptoms of AD and make a diagnosis in order to provide cost-effective therapies...
  17. ncbi Interdisciplinary approaches to Alzheimer's disease management
    Elizabeth A Crooks
    Frances Payne Bolton School of Nursing, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA
    Clin Geriatr Med 20:121-39. 2004
  18. ncbi MR tractography depicting damage to the arcuate fasciculus in a patient with conduction aphasia
    David S Geldmacher
    Neurology 69:321; author reply 321-2. 2007
  19. ncbi Development of a scale to predict decline in patients with mild Alzheimer's disease
    Concepcion E Santillan
    University Memory and Aging Center, University Hospitals of Cleveland, and Department of Neurology, Case Western Reserve University, Ohio 44120, USA
    J Am Geriatr Soc 51:91-5. 2003
    ..To develop a scale that can assist in predicting likelihood of decline from mild dementia over 1 year in patients with Alzheimer's disease (AD)...
  20. ncbi Optimizing coding and reimbursement to improve management of Alzheimer's disease and related dementias
    Howard Fillit
    Institute for the Study of Aging, New York, New York 10153, USA
    J Am Geriatr Soc 50:1871-8. 2002
    ....

Research Grants3

  1. Pioglitazone in Alzheimer's Disease Progression
    David Geldmacher; Fiscal Year: 2001
    ..Comparison of mean differences (using last observation carried forward imputation techniques) and survival analyses will be employed to assess for group differences in clinical measures AD of progression. ..
  2. Pioglitazone in Alzheimer's Disease Progression
    David Geldmacher; Fiscal Year: 2002
    ..Comparison of mean differences (using last observation carried forward imputation techniques) and survival analyses will be employed to assess for group differences in clinical measures AD of progression. ..
  3. Pioglitazone in Alzheimer's Disease Progression
    David Geldmacher; Fiscal Year: 2003
    ..Comparison of mean differences (using last observation carried forward imputation techniques) and survival analyses will be employed to assess for group differences in clinical measures AD of progression. ..